» Articles » PMID: 36762807

The Role of Hypoxia in Brain Tumor Immune Responses

Overview
Date 2023 Feb 10
PMID 36762807
Authors
Affiliations
Soon will be listed here.
Abstract

Oxygen is a vital component of living cells. Low levels of oxygen in body tissues, known as hypoxia, can affect multiple cellular functions across a variety of cell types and are a hallmark of brain tumors. In the tumor microenvironment, abnormal vasculature and enhanced oxygen consumption by tumor cells induce broad hypoxia that affects not only tumor cell characteristics but also the antitumor immune system. Although some immune reactions require hypoxia, hypoxia generally negatively affects immunity. Hypoxia induces tumor cell invasion, cellular adaptations to hypoxia, and tumor cell radioresistance. In addition, hypoxia limits the efficacy of immunotherapy and hinders antitumor responses. Therefore, understanding the role of hypoxia in the brain tumor, which usually does not respond to immunotherapy alone is important for the development of effective anti-tumor therapies. In this review, we discuss recent evidence supporting the role of hypoxia in the context of brain tumors.

Citing Articles

Marine Lectins and Lectin-like Proteins as Promising Molecules Targeting Aberrant Glycosylation Signatures in Human Brain Tumors.

Buriak I, Kumeiko V Mar Drugs. 2024; 22(12).

PMID: 39728102 PMC: 11679326. DOI: 10.3390/md22120527.


A novel immune-related gene prognostic signature combining immune cell infiltration and immune checkpoint for glioblastoma patients.

Liu X, Liu X Transl Cancer Res. 2024; 13(11):6136-6153.

PMID: 39697704 PMC: 11651773. DOI: 10.21037/tcr-24-562.


Harnessing type I interferon-mediated immunity to target malignant brain tumors.

Lim J, Kang I, La J, Ku K, Kang B, Kim Y Front Immunol. 2023; 14:1203929.

PMID: 37304294 PMC: 10247981. DOI: 10.3389/fimmu.2023.1203929.

References
1.
Omuro A, Brandes A, Carpentier A, Idbaih A, Reardon D, Cloughesy T . Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro Oncol. 2022; 25(1):123-134. PMC: 9825306. DOI: 10.1093/neuonc/noac099. View

2.
Louveau A, Smirnov I, Keyes T, Eccles J, Rouhani S, Peske J . Structural and functional features of central nervous system lymphatic vessels. Nature. 2015; 523(7560):337-41. PMC: 4506234. DOI: 10.1038/nature14432. View

3.
Godfrey D, Le Nours J, Andrews D, Uldrich A, Rossjohn J . Unconventional T Cell Targets for Cancer Immunotherapy. Immunity. 2018; 48(3):453-473. DOI: 10.1016/j.immuni.2018.03.009. View

4.
Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J . Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res. 2019; 38(1):87. PMC: 6380009. DOI: 10.1186/s13046-019-1085-3. View

5.
Hayek I, Fischer F, Schulze-Luehrmann J, Dettmer K, Sobotta K, Schatz V . Limitation of TCA Cycle Intermediates Represents an Oxygen-Independent Nutritional Antibacterial Effector Mechanism of Macrophages. Cell Rep. 2019; 26(13):3502-3510.e6. DOI: 10.1016/j.celrep.2019.02.103. View